BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Fintepla (Fenfluramine) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Fintepla (Fenfluramine)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06598449-8885@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fintepla (Fenfluramine): Phase 4 readout est. (NCT06598449)
DESCRIPTION:Fintepla (Fenfluramine)\, phase 4\, Epilepsy.\nStudy: Assessmen
 t of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Un
 der 24 Months of Age\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/fenfluramine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06598449
URL:https://assetmemo.bio/drug/fenfluramine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04289467-8885@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fintepla (Fenfluramine): Phase 2 readout est. (NCT04289467)
DESCRIPTION:Fintepla (Fenfluramine)\, phase 2\, Epilepsy.\nStudy: Treatment
  of Refractory Infantile Spasms With Fenfluramine\nEstimated primary compl
 etion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/fenfluramine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04289467
URL:https://assetmemo.bio/drug/fenfluramine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07112365-8885@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Fintepla (Fenfluramine): Phase 4 readout est. (NCT07112365)
DESCRIPTION:Fintepla (Fenfluramine)\, phase 4\, Epilepsy.\nStudy: The FINTE
 PLA as an Anti-SUDEP Therapy in Dravet Syndrome Project\nEstimated primary
  completion: 30 September 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/fenfluramine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07112365
URL:https://assetmemo.bio/drug/fenfluramine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05064878-8885@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20271108
DTEND;VALUE=DATE:20271109
SUMMARY:Fintepla (Fenfluramine): Phase 3 readout est. (NCT05064878)
DESCRIPTION:Fintepla (Fenfluramine)\, phase 3\, Epilepsy.\nStudy: A Phase 3
  Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 
 Deficiency Disorder.\nEstimated primary completion: 8 November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/fenfluramine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05064878
URL:https://assetmemo.bio/drug/fenfluramine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07651293-8885@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Fintepla (Fenfluramine): Phase na readout est. (NCT07651293)
DESCRIPTION:Fintepla (Fenfluramine)\, phase na.\nStudy: Using Fenfluramine 
 to Test the Serotonin Deficiency Theory of Depression\nEstimated primary c
 ompletion: July 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /fenfluramine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07651293
URL:https://assetmemo.bio/drug/fenfluramine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503444-8885@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20290206
DTEND;VALUE=DATE:20290207
SUMMARY:Fintepla (Fenfluramine): Phase 3 readout est. (NCT07503444)
DESCRIPTION:Fintepla (Fenfluramine)\, phase 3\, Rett Syndrome.\nStudy: A Ph
 ase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome\nEstimated prim
 ary completion: 6 February 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/fenfluramine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07503444
URL:https://assetmemo.bio/drug/fenfluramine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
